Overdiagnosis
Overdiagnosis is the diagnosis of "disease" that will never cause symptoms or death during a patient's ordinarily expected lifetime. Overdiagnosis is a side effect of screening for early forms of disease. Although screening saves lives in some cases, in others it may turn people into patients unnecessarily and may lead to treatments that do no good and perhaps do harm. Given the tremendous variability that is normal in biology, it is inherent that the more one screens, the more incidental findings will generally be found. For a large percentage of them, the most appropriate medical response is to recognize them as something that does not require intervention; but determining which action a particular finding warrants can be very difficult, whether because the differential diagnosis is uncertain or because the risk ratio is uncertain.
Overdiagnosis occurs when a disease is diagnosed correctly, but the diagnosis is irrelevant. A correct diagnosis may be irrelevant because treatment for the disease is not available, not needed, or not wanted. Some people contend that the term "overdiagnosis" is inappropriate, and that "overtreatment" is more representative of the phenomenon.
Because most people who are diagnosed are also treated, it is difficult to assess whether overdiagnosis has occurred in an individual. Overdiagnosis in an individual cannot be determined during life. Overdiagnosis is only certain when an individual remains untreated, never develops symptoms of the disease and dies of something else. Thus most of the inferences about overdiagnosis comes from the study of populations. Rapidly rising rates of testing and disease diagnosis in the setting of stable rates of the feared outcome of the disease are highly suggestive of overdiagnosis. Most compelling, however, is evidence from a randomized trial of a screening test intended to detect pre-clinical disease. A persistent excess of detected disease in the tested group years after the trial is completed constitutes the best evidence that overdiagnosis has occurred.
Although overdiagnosis is potentially applicable to the diagnosis of any disease, its origin is in cancer screening—the systematic evaluation of asymptomatic patients to detect early forms of cancer. The central harm of cancer screening is overdiagnosis—the detection of abnormalities that meet the pathologic definition of cancer but will never progress to cause symptoms or death during a patient's ordinarily expected lifetime.
Overdiagnosis and the variability of cancer progression
Cancer screening is the effort to detect cancer early, during its pre-clinical phase—the time period that begins with an abnormal cell and ends when the patient notices symptoms from the cancer. It has long been known that some people have cancers with short pre-clinical phases, while others have cancers with long pre-clinical phases. And this heterogeneity has an unfortunate implication: namely, screening tends to disproportionately detect slow-growing cancers and disproportionately miss the fast-growing cancers —the very cancers we would most like to catch. For more information, see Screening #Length time bias.This long-standing model has a hidden assumption: namely, that all cancers inevitably progress. But some pre-clinical cancers will not progress to cause problems for patients. And if screening detects these cancers, overdiagnosis has occurred.
The figure below depicts the heterogeneity of cancer progression using 4 arrows to represent 4 categories of cancer progression.
The arrow labeled "Fast" represents a fast-growing cancer, one that quickly leads to symptoms and to death. These are the worst forms of cancer and unfortunately often appear in the interval between screening tests. The arrow labeled "Slow" represents a slow-growing cancer, one that leads to symptoms and death but only after many years. These are the cancers for which screening has arguably the greatest beneficial impact.
The arrow labeled "Very Slow" represents a cancer that never causes problems because it is growing very slowly. If a cancer grows slowly enough, then patients will die of some other cause before the cancer gets big enough to produce symptoms. This is particularly likely with small cancers in the elderly—prostate cancer in older men serves as the most prominent clinical example.
The arrow labeled "Non-progressive" represents a cancer that never causes problems because it is not growing at all. In other words, there are cellular abnormalities that meet the pathologic definition of cancer but never grow to cause symptoms—alternatively, they may grow and then regress. Although the concept of non-progressive cancers may seem implausible, basic scientists have begun to uncover biologic mechanisms that halt the progression of cancer. Some cancers outgrow their blood supply, others are recognized by the host's immune system, and some are not that aggressive in the first place.
Overdiagnosis occurs when either "Non-progressive" cancers or "Very Slow" growing cancers are detected. These two forms of cancer are collectively referred to as pseudodisease—literally false disease. Since the word "disease" implies something that makes, or will make, a person feel sick, pseudodisease is an appropriate word for describing these abnormalities. Thus, another definition of overdiagnosis is simply the detection of pseudodisease.
Evidence for overdiagnosis in cancer
The phenomenon of overdiagnosis is most widely understood in prostate cancer. A dramatic increase in the number of new cases of prostate cancer was observed following the introduction of the PSA screening test. Because of the problem of overdiagnosis, most organizations recommend against prostate cancer screening in men with limited life expectancy—generally defined as less than 10 years.Overdiagnosis has been identified in mammographic screening for breast cancer. Long-term follow-up of the Malmo randomized trial of mammography found a persistent excess of 115 breast cancers in the screened group 15 years after the trial was completed. In a letter to the editor, authors not associated with the original study of the data from the randomized clinical trial argued that one-quarter of mammographically detected breast cancers represent overdiagnosis. A systematic review of mammography screening programs reported a overdiagnosis rate of around 50%, which is the same of saying that a third of diagnosed cases of breast cancer are overdiagnosed.
Overdiagnosis has also been identified in chest x-ray screening for lung cancer. Long-term follow-up of the Mayo Clinic randomized trial of screening with chest x-rays and sputum cytology found a persistent excess of 46 lung cancer cases in the screened group 13 years after the trial was completed, suggesting that 20–40% of lung cancers detected by conventional x-ray screening represent overdiagnosis. There is considerable evidence that the problem of overdiagnosis is much greater for lung cancer screening using spiral-CT scans
Overdiagnosis has also been associated with early detection in a variety of other cancers, including neuroblastoma, melanoma, and thyroid cancer. In fact, some degree of overdiagnosis in cancer early detection is probably the rule, not the exception.
Evidence for overdiagnosis of infectious diseases
Issues with overdiagnosis of infectious diseases, such as malaria or typhoid fever, persist in many regions around the world. For example, malaria overdiagnosis is well-documented in African countries and results in over-inflation of actual malaria rates reported at the local and national levels. Health facilities tend to over-diagnose malaria in patients presenting with symptoms such as fever, due to traditional perceptions and issues related to laboratory testing. Therefore, malaria overdiagnosis leads to under-management of other fever-inducing conditions, but also to over-prescription of antimalarial drugs.Harms of overdiagnosis
Overdiagnosed patients cannot benefit from the detection and treatment of their "cancer" because the cancer was never destined to cause symptoms or death. They can only be harmed. There are three categories of harm associated with overdiagnosis:- Physical effects of unnecessary diagnosis and treatment: All medical interventions have side effects. This is particularly true of cancer treatments. Surgery, radiation and chemotherapy all pose varying morbidity and mortality risks.
- Psychological effects: there is a burden for an individual simply being labeled as "diseased" and an associated increased sense of vulnerability.
- Economic burden: Not only the associated cost of treatment, but also—at least, in the current health care system in the United States—a potential increase in the cost of health insurance or even an inability to procure it. Similar issues may arise with life insurance. Unlike health insurance, life insurance does not fall under the scope of the Affordable Care Act, thus insurers have even more leeway in denying or reducing coverage or inflating premiums due to the patient's condition.
Distinction among overdiagnosis, misdiagnosis, and false positive results
Overdiagnosis is often confused with the term "false positive" test results and with misdiagnosis, but they are three distinct concepts. A false positive test result refers to a test that suggests the presence of disease, but is ultimately proved to be in error. Patients with false positive test results may be told that they have a disease and erroneously treated; overdiagnosed patients are told they have disease and generally receive treatment. Misdiagnosed patients do not have the condition at all, or have a totally different condition, but are treated anyway.Overdiagnosis is also distinct from overtesting. Overtesting is the phenomenon where patients receive a medical test that they don't need; it will not benefit them. For instance, a patient that receives a lumbar spine x-ray when they have low back pain without any sinister signs or symptoms and symptoms have been present for less than 4 weeks. Most tests are subject to overtesting, but echocardiograms have been shown to be particularly prone to overtesting. The detection of overtesting is difficult; recently, many population-level estimates have emerged to try to detect potential overtesting. The most common of these estimates is geographical variation in test use. These estimates detect regions, hospitals or general practices that order many more tests, compared to their peers, irrespective of differences in patient demographics between regions. Further methods that have been used include identifying general practices that order a higher proportion of tests that return a normal result, and the identification of tests with large temporal increases in their use, without a justifiable reason.
| Overdiagnosis | False Positive Results | Misdiagnosis | |
| Definition | Detection of a "disease" that will never cause symptoms or death during a patient’s lifetime | A "false alarm"—an initial test result that suggests the presence of disease, but later proved false | Diagnosis of a disease that the patient does not in fact have |
| Patient experience | Told they have the disease | Told that the test was wrong and they do not have the disease | Told they have the disease |
| Physician action | Generally, initiates treatment | Reassurance | Generally, initiates treatment |
| Potential Harms |
|
Overdiagnosis bias in survival statistics
Overdiagnosis, by contributing disproportionately to early diagnosis of lethal conditions, has the effect of inflating survival statistics. The more overdiagnosis, the better survival appears. This looks like early diagnosis is doing good. More testing is encouraged, leading to more overdiagnosis.Overdiagnosis always inflates survival statistics. Survival rates are calculated as the proportion of patients that are alive after a fixed period following diagnosis. Overdiagnosis inflates both the numerator and denominator of the survival statistic. The figure below shows how overdiagnosis—the detection of pseudodisease—inflates the survival statistic even when the number of deaths is stable.
Imagine that there is no pseudodisease detected in current practice and that among 1000 patients diagnosed, only 100 are alive 10 years later. Now imagine that in addition to identifying these cancers, spiral CT scanning also identifies 4000 patients with pseudodisease—all of whom survive 10 years, since they have non-progressive cancer. The new 10-year survival will include these patients in both the numerator and denominator—leading to a 10-year survival of 4100 divided by 5000 or 82%. Note that even though survival has changed dramatically, the number of people who die has not changed—under either condition 900 patients have died. This example demonstrates how survival rates can be increased by overdiagnosis, even if no one avoids death.
Solutions to overdiagnosis
Removing "cancer" from names of low-risk diagnoses
It has been proposed that some pre-malignant conditions have the words cancer or carcinoma removed from their name. Another proposal is to name conditions Indolent Lesions of Epithelial Origin or IDLE.An analogy can be made with Neisseria meningitidis, a bacterium present in 5–15% of the adult population that can potentially cause life-threatening meningitis. To say that those who carry the microorganism "have meningitis" would be misleading.